SBC Medical Group’s Buy-Extended Rating Stands with $9.00 Price Target
Emerging Growth Research maintained SBC Medical Group’s Buy-Extended rating and $9.00 price target, implying substantial upside from its $3.65 closing price on April 21, 2026. It highlighted a 3% founder stake cut without dilution, a boost to roughly 20% public float and strategic international M&A, AI operations and longevity-focused services.
1. Rating and Price Target Reiteration
Emerging Growth Research maintained its Buy-Extended rating on SBC Medical Group Holdings and held a 12-month price target of $9.00, suggesting significant upside from the $3.65 closing share price on April 21, 2026.
2. Secondary Share Transaction Impact
A recent secondary share issuance reduced the founder’s ownership by approximately 3% without diluting existing shareholders, lifting public float to about 20%, which may enhance trading liquidity and attract institutional investors.
3. Growth Outlook and Strategic Initiatives
Management anticipates a return to revenue growth in 2026 after pricing-related pressure in 2025 and is advancing international M&A, AI-driven operational projects and longevity-focused service expansions to drive long-term growth.